Paul Tudor Jones’s Pliant Therapeutics PLRX Stock Holding History

Paul Tudor Jones’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9K	Hold	29,729	–	–	﹤0.01%	3440
2026 Q1	$37.5K	Hold	29,729	–	–	﹤0.01%	3496
2025 Q4	$36.3K	Hold	29,729	–	–	﹤0.01%	3404
2025 Q3	$44K	Hold	29,729	–	–	﹤0.01%	3280
2025 Q2	$34.5K	Sell	29,729 -203	-0.7%	-$287	﹤0.01%	3170
2025 Q1	$40.4K	Buy	+29,932	New	+$182K	﹤0.01%	2964
2024 Q4	–	Sell	-22,628	Closed	-$254K	–	3402
2024 Q3	$254K	Sell	22,628 -9,618	-30%	-$120K	﹤0.01%	2406
2024 Q2	$347K	Buy	32,246 +5,349	+20%	+$69K	﹤0.01%	1961
2024 Q1	$401K	Buy	+26,897	New	+$444K	﹤0.01%	1746
2023 Q3	–	Sell	-27,725	Closed	-$502K	–	2739
2023 Q2	$502K	Sell	27,725 -18,482	-40%	-$438K	0.01%	1711
2023 Q1	$1.23M	Buy	46,207 +22,078	+91%	+$629K	0.02%	1069
2022 Q4	$466K	Buy	24,129 +153	+0.6%	+$3.2K	0.01%	1627
2022 Q3	$501K	Buy	+23,976	New	+$459K	0.01%	1393

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Paul Tudor Jones's PLRX Position: Q2 2026 in Review

Paul Tudor Jones held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 29,729 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3440.

Paul Tudor Jones first reported a position in PLRX in Q3 2022 and has held it in 13 quarters since. The position peaked at $1.23M in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Paul Tudor Jones held 29,729 shares of Pliant Therapeutics worth $33.9K as of Q2 2026.
Paul Tudor Jones left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3440 holding.
Paul Tudor Jones first reported a position in Pliant Therapeutics in Q3 2022 and has held it in 13 quarters since.
Paul Tudor Jones's Pliant Therapeutics position peaked at $1.23M in Q1 2023.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.